<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242694</url>
  </required_header>
  <id_info>
    <org_study_id>LAMPP 1.0</org_study_id>
    <nct_id>NCT03242694</nct_id>
  </id_info>
  <brief_title>Left Atrial Function Analysis for Patients With Persistent Atrial Fibrillation Undergoing Pulmonary Vein Isolation</brief_title>
  <acronym>LAMPP</acronym>
  <official_title>Left Atrial Function Analysis With Multimodal Techniques for Patients With Persistent Atrial Fibrillation Undergoing Pulmonary Vein Isolation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University Heart and Vascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University Heart and Vascular Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study is designed to describe the factors determining the
      success of pulmonary vein isolation (PVI) for patients with persistent atrial fibrillation
      (AF). These factors - described as left atrial (LA) function - are simultaneously studied by
      multi-modal techniques in patients undergoing radiofrequency ablation. The simultaneous
      measurements are conducted before the PVI in AF and after the sinus rhythm converted due to
      PVI. These measurements include invasive LA pressure monitoring, LA voltage map creation, LA
      strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining
      biomarkers from blood samples. During the one year follow-up period rhythm monitoring is
      conducted by regular Holter-monitoring. Our aim is to define the predictive values of the
      above mentioned factors and to create a new score system for predicting PVI success in
      persistent AF population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>one-year success of pulmonary vein isolation</measure>
    <time_frame>3-12 months after the first pulmonary vein isolation</time_frame>
    <description>one-year success without recurrent atrial fibrillation or atrial tachycardia without antiarrhythmic drugs after the three-month blanking period of pulmonary vein isolation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute unsuccessful pulmonary vein isolation</measure>
    <time_frame>within 5 minutes after the last application is performed at the ablation procedure</time_frame>
    <description>operator is unable to disconnect pulmonary veins from the left atrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>usage of antiarrhythmic drugs after the three-month blanking period</measure>
    <time_frame>3-12 months after the first pulmonary vein isolation</time_frame>
    <description>antiarrhythmic drugs: sotalol, amiodarone, propafenon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reablation</measure>
    <time_frame>3-12 months after the first pulmonary vein isolation</time_frame>
    <description>repeated left atrial ablation is performed due to atrial fibrillation or left atrial tachycardia recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major complications of pulmonary vein isolation</measure>
    <time_frame>through 1 year follow-up after the first pulmonary vein isolation</time_frame>
    <description>major complications: requiring surgical intervention or causing prolonged hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>through 1 year follow-up after the first pulmonary vein isolation</time_frame>
    <description>major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>through 1 year follow-up after the first pulmonary vein isolation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>persistent atrial fibrillation</arm_group_label>
    <description>invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LA pressure, voltage map, strain, scar-map, blood sampling</intervention_name>
    <description>invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm</description>
    <arm_group_label>persistent atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pulmonary vein isolation</intervention_name>
    <description>pulmonary vein isolation without creating additional ablation lesions</description>
    <arm_group_label>persistent atrial fibrillation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent atrial fibrillation referred for pulmonary vein isolation at Heart
        and Vascular Center of Semmelweis University, Budapest, Hungary.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented, symptomatic persistent atrial fibrillation (AF)

          -  catheter ablation is indicated

          -  aged 18-75 years

          -  signed Patient Informed Consent Form

          -  able and willing to comply with all pre-, post-, and follow-up testing and
             requirements

        Exclusion Criteria:

          -  secondary AF

          -  paroxysmal, long-standing persistent or permanent AF

          -  ejection fraction &lt; 30%

          -  GFR &lt;30 ml/min/1.73m2

          -  unstable angina pectoris or myocardial infarction within the past 2 months

          -  severe heart failure (NYHA IV)

          -  severe COPD (GOLD III-IV)

          -  previous left atrial catheter ablation

          -  previous transthoracic cardiac surgery

          -  implanted cardiac device (pacemaker, ICD, CRT, VAD)

          -  awaiting cardiac transplantation or other cardiac surgery within the next 12 months

          -  any contraindication for pulmonary vein isolation, MRI or anticoagulation

          -  coagulopathy

          -  active malignancy, left atrial myxoma

          -  autoimmune disorder, chronic inflammatory disease

          -  acute illness, active systemic infection, sepsis

          -  women who are pregnant, breast feeding, or planning to become pregnant in the next 12
             months

          -  aged under 18 years or above 75 years

          -  enrollment in other studies, which exclude participation in other studies

          -  patient not willing or not able to sign the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Geller, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart and Vascular Center of Semmelweis University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bela Merkely, MD PhD DSc</last_name>
    <role>Study Director</role>
    <affiliation>Heart and Vascular Center of Semmelweis University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Szilvia Herczeg, MD</last_name>
    <phone>0036206663198</phone>
    <email>herczeg.szilvia@med.semmelweis-univ.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nandor Szegedi, MD</last_name>
    <phone>0036206663442</phone>
    <email>szegedi.nandor@med.semmelweis-univ.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart and Vascular Center of Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Perge, MD</last_name>
      <phone>0036208259612</phone>
      <email>perge.peter@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>left atrial function</keyword>
  <keyword>left atrial pressure</keyword>
  <keyword>voltage map</keyword>
  <keyword>strain</keyword>
  <keyword>scar</keyword>
  <keyword>success</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

